12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMG 145: Phase Ib data

A double-blind, dose-escalation Phase Ib trial in 51 patients with high cholesterol who were receiving stable doses of statins showed that subcutaneous AMG 145 given every 2 weeks reduced mean LDL-C by up to 75% vs. placebo at week 6 in patients on low to moderate doses of statins and by up to 63% vs. placebo at week 6 in patients receiving high doses of statins (p<0.001 for both). Additionally, subcutaneous...

Read the full 332 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >